This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Climb Bio (CLYM) and Henry Schein (HSIC)

Tipranks - Thu May 7, 5:00AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on QuidelOrtho (QDEL), Climb Bio (CLYM) and Henry Schein (HSIC).

Claim 55% Off TipRanks

QuidelOrtho (QDEL)

William Blair analyst Andrew Brackmann maintained a Hold rating on QuidelOrtho today and set a price target of $11.66. The company’s shares closed last Tuesday at $11.66.

According to TipRanks.com, Brackmann is a 4-star analyst with an average return of 10.3% and a 44.4% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

QuidelOrtho has an analyst consensus of Hold, with a price target consensus of $18.42, which is a 48.1% upside from current levels. In a report issued on April 21, TipRanks – xAI also reiterated a Hold rating on the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

Climb Bio (CLYM)

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Climb Bio, with a price target of $19.00. The company’s shares closed last Tuesday at $11.45, close to its 52-week high of $11.55.

According to TipRanks.com, Harrison is a top 100 analyst with an average return of 46.0% and a 56.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Mereo Biopharma Group Plc. ;'>

Climb Bio has an analyst consensus of Strong Buy, with a price target consensus of $18.25, an 83.8% upside from current levels. In a report issued on April 20, TipRanks – Google also upgraded the stock to Buy with a $10.00 price target.

Henry Schein (HSIC)

BTIG analyst David Larsen maintained a Hold rating on Henry Schein yesterday. The company’s shares closed last Tuesday at $74.37.

According to TipRanks.com, Larsen is ranked 0 out of 5 stars with an average return of -8.2% and a 33.3% success rate. Larsen covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Definitive Healthcare Corp, and Hims & Hers Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $89.00 average price target, representing a 24.5% upside. In a report released yesterday, TipRanks – Google also downgraded the stock to Hold with a $75.00 price target.

Read More on QDEL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.